Safety of Certolizumab Pegol in Chronic Plaque Psoriasis: Cumulative Data Over 48 Weeks’ Exposure from Phase 3, Multicenter, Randomized, Placebo-Controlled Studies. (2018). SKIN The Journal of Cutaneous Medicine, 2(S1), S16. https://doi.org/10.25251/skin.2.supp.16